Global Mycobacterium Infections Treatment Market, By Drugs (Isoniazid, Ethambutol, Rifampin, Others), Indication (Tuberculosis, Leprosy, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Mycobacterium Infections Treatment Market Analysis and Size
The global mycobacterium infections treatment market is expected to witness significant growth during the forecast period. Mycobacterium infections treatment market is boosted by the rising cases of mycobacterium infectious diseases and increase in research and development activities conducted by major market players. The most highly observed mycobaterial infectious disease is tuberculosis. Regarding its treatment, some strains are highly resistant to antibiotics but there are a few species that antibiotics can affect such as rifamycin and clarithromycin. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global mycobacterium infections treatment market in the forecast period 2022-2029. The expected CAGR of global mycobacterium infections treatment market is tend to be around 6.50% in the mentioned forecast period. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Mycobacterium infections are the type of multisystem infections caused by a pathogen called mycobacteriaceae. The good causes of mycobacterium infections are still under investigation. Mycobacterium infections are often categorized as asymptomatic as they do not show specific symptoms. Many patients do not show any symptoms; thus, treating and managing the disease is difficult.
Mycobacterium Infections Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drugs (Isoniazid, Ethambutol, Rifampin, Others), Indication (Tuberculosis, Leprosy, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
AstraZeneca (U.K.), Lilly (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Novartis AG (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), GSK plc (U.K.), Hikma Pharmaceuticals PLC (U.K.), Cipla Inc. (India), STI Pharma, LLC (U.S.)
|
|
Market Opportunities
|
|
Global Mycobacterium Infections Treatment Market Dynamics
Drivers
- Increased Cases of Mycobacterium abscessus
The increasing prevalence of mycobacterium abscessus is expected to boost the market growth. Around 4.66–5.78% of the population witnessed mycobacterium infections globally at the end of 2020. Thus, this rising cases are demanding for higher treatment types and consequently boosting the market growth.
- Growing Demand for Advanced Diagnostic Techniques
Scientists are developing advanced techniques for the betterment of patients. DNA fingerprinting technology is an efficient diagnostic tool that is used for diagnosing these infections. Precise diagnosis and accurate identification of the disease-causing mycobacterial species lead to the decision of the right treatment.
Opportunities
- Increasing Treatment Approaches
Several antibiotics are helpful for the treatment of these infectious diseases. Researchers continuously try to find a proper treatment solution for several mycobacterial infections. The market for mycobacterial conditions treatment is progressively growing due to the increased prevalence of infectious diseases and limited treatment options. This creates more opportunities to the market.
- Increasing Demand for Retail Pharmacies
The rise in the number of mycobacterium infections therapeutics being delivered through retail pharmacies and the increase in the number of retail pharmacies in highly developed countries create much opportunities for the market growth. In addition to this, patients choose retail pharmacies for purchasing drugs, as these are easily feasible.
Restraints/Challenges
- Lack of skilled professionals
The lack of trained who cannot treat the patients with appropriate treatments could curb the growth of the global mycobacterium infections treatment market during a forecast period.
- High Cost
The huge expenditure associated with mycobacterium abscessus medications hamper the market growth. Combined therapy is widely used to treat this disease, including prolonged treatment with combined surgical drainage, antimicrobial agents, and debridement. BCG vaccines provide protection to a great extent for longer duration. And all of these factors lead to higher cost of the treatment.
This global mycobacterium infections treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global mycobacterium infections treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Mycobacterium Infections Treatment Market
COVID-19 has left a major global public health crisis that has impacted practically every business. Its long-term consequences are expected to influence industry growth during the forecast period.
Although during the pandemic, the attention was mainly driven towards the COVID-19 patients and hospitals and clinics were occupied with these patients. Still, in the post-pandemic era, the biotechnology and pharmaceutical industries are expected to witness a huge growth in the future, as research and treatments are drifting towards normal patients again. Thus, this will significantly impact the global mycobacterium infections treatment market.
Global Mycobacterium Infections Treatment Market Scope
The global mycobacterium infections treatment market is segmented on the basis of drug, indication, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug
- Isoniazid
- Ethambutol
- Rifampin
- Others
Indication
- Tuberculosis
- Leprosy
- Others
Route of Administration
- Oral
- Parenteral
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Mycobacterium Infections Treatment Market Regional Analysis/Insights
The global mycobacterium infections treatment market is analysed and market size insights and trends are provided by drug, indication, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global mycobacterium infections treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has been witnessing a positive growth for global mycobacterium infections treatment market throughout the forecasted period due to the high prevalence of infectious diseases, sophisticated medical facilities and rise in government initiatives.
Asia-Pacific dominates the market due to the key generic players and increases focuses on the research and development activity.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Mycobacterium Infections Treatment Market Share Analysis
The global mycobacterium infections treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global mycobacterium infections treatment market.
Key players operating in the global mycobacterium infections treatment market include:
- AstraZeneca (U.K.)
- Lilly (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Novartis AG (Switzerland)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Merck & Co., Inc. (U.S.)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Hikma Pharmaceuticals PLC (U.K.)
- Cipla Inc. (India)
- STI Pharma, LLC (U.S.)
SKU-